Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPS-ZM1 for Post-Operative Cerebral Edema in Glioblastoma
NCT07791264Phase 1Not yet recruiting
- Sponsor
- City of Hope
- Start
- Feb 2027
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of FPS-ZM1 in cerebral edema and glioblastoma (GBM) (2 arms), sponsored by City of Hope. Primary endpoints: FPS-ZM1 related adverse events and Dose limiting toxicity rate. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
FPS-ZM1
03
Conditions
cerebral edemaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT07791264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791264.